Portfolio Holdings Detail for ISIN IE00BYXG2H39

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE

Holdings detail for ONC

Show aggregate ONC holdings

News associated with ONC

BeOne Medicines (NASDAQ:ONC) CEO Sells $9,055,715.13 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 27,803 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total value of $9,055,715.13. The sale was disclosed in a document filed with […] - 2025-09-21 06:27:00

BeOne Medicines (NASDAQ:ONC) Shares Gap Down Following Insider Selling

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report)’s stock price gapped down before the market opened on Wednesday following insider selling activity. The stock had previously closed at $351.13, but opened at $324.49. BeOne Medicines shares last traded at $325.00, with a volume of 326,240 shares. Specifically, Director Corazon (Corsee) D. Sanders […] - 2025-09-12 02:22:44

Oncolytics Biotech (TSE:ONC) Stock Passes Above 200-Day Moving Average – Here’s What Happened

Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$1.96 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares. Analyst Ratings Changes Several equities analysts have recently […] - 2025-09-09 05:16:49

Insider Selling: BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Sells $12,182,876.16 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 39,936 shares of the firm’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $305.06, for a total value of $12,182,876.16. The transaction was disclosed in a document filed with the Securities […] - 2025-08-18 05:55:08

Chan Henry Lee Sells 11,013 Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) SVP Chan Henry Lee sold 11,013 shares of the firm’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $300.45, for a total value of $3,308,855.85. The transaction was disclosed in a filing with the SEC, […] - 2025-08-18 05:55:08

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Sells $15,164,809.28 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 49,858 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $304.16, for a total value of $15,164,809.28. The sale was disclosed in a legal filing with the […] - 2025-08-18 05:14:56

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $327.56 Average Target Price from Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated […] - 2025-08-05 02:08:53

BeOne Medicines (NASDAQ:ONC) Upgraded by Wall Street Zen to Buy Rating

BeOne Medicines (NASDAQ:ONC – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday. ONC has been the subject of several other reports. TD Securities reaffirmed a “buy” rating and issued a $334.00 target […] - 2025-07-28 04:18:54

BeOne Medicines (NASDAQ:ONC) Rating Lowered to Hold at Wall Street Zen

BeOne Medicines (NASDAQ:ONC – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday. Other analysts have also issued reports about the stock. Morgan Stanley upped their price target on shares of BeOne […] - 2025-07-14 03:00:47

Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Price Target at $320.67

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) has been given a consensus recommendation of “Buy” by the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage […] - 2025-07-11 02:14:46

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) has been given an average rating of “Buy” by the six research firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on […] - 2025-06-18 04:30:52

Oncolytics Biotech (TSE:ONC) Stock Passes Below 200-Day Moving Average – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$0.95 and traded as low as C$0.80. Oncolytics Biotech shares last traded at C$0.87, with a volume of 194,637 shares traded. Wall Street Analyst Weigh In Separately, […] - 2025-06-17 05:03:26

Beigene (NASDAQ:ONC) Stock Price Down 0.1% Following Insider Selling

Beigene, Ltd. (NASDAQ:ONC – Get Free Report) dropped 0.1% on Tuesday after an insider sold shares in the company. The company traded as low as $260.46 and last traded at $263.42. Approximately 416,160 shares traded hands during trading, a decline of 8% from the average daily volume of 450,640 shares. The stock had previously closed […] - 2025-06-11 02:28:42

We Did The Math FTHI Can Go To $24

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-02 07:11:28

Analysts Set Beigene, Ltd. (NASDAQ:ONC) PT at $319.00

Shares of Beigene, Ltd. (NASDAQ:ONC – Get Free Report) have been given a consensus rating of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on […] - 2025-05-22 02:46:44

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

Resilient and growing. Those two descriptions definitely apply to the healthcare sector. People need healthcare products and services regardless of what's happening with the economy. And with elderly populations increasing in many countries (including the U.S.), the demand for he - 2025-05-21 05:48:00

Beigene (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Beigene (NASDAQ:ONC – Free Report) in a research report sent to investors on Monday,Benzinga reports. Royal Bank of Canada currently has a $312.00 price target on the stock. Several other equities research analysts have also issued reports on ONC. Macquarie raised their target price […] - 2025-04-29 04:54:56

Beigene (NASDAQ:ONC) Shares Gap Up After Analyst Upgrade

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s share price gapped up prior to trading on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $311.00 to $317.00. The stock had previously closed at $229.22, but opened at $249.41. JPMorgan Chase & Co. currently has an overweight rating on the stock. […] - 2025-04-23 02:50:49

Beigene (NASDAQ:ONC) Upgraded at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Beigene (NASDAQ:ONC – Free Report) to a moderate buy rating in a research report sent to investors on Monday, MarketBeat Ratings reports. Royal Bank of Canada currently has $312.00 price objective on the stock. A number of other equities analysts also recently weighed in on the stock. Bank […] - 2025-04-10 03:04:51

Beigene (NASDAQ:ONC) Shares Gap Down After Insider Selling

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $271.80, but opened at $255.83. Beigene shares last traded at $245.79, with a volume of 250,731 shares traded. Specifically, Director Bros. Advisors Lp Baker sold 732,827 shares of the […] - 2025-03-04 04:37:12

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ONC holdings

Share Trades of ONC by Blackrock for IE00BYXG2H39

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-06	BUY	165	344.530	346.000	345.853	GBX 57,066	261.53
2025-10-03	BUY	385	343.870	347.090	346.768	GBX 133,506	261.09
2025-10-02	BUY	55	345.170	355.300	354.287	GBX 19,486	260.63
2025-09-30	BUY	110	340.700	342.260	342.104	GBX 37,631	259.77
2025-09-26	BUY	110	326.060	330.000	329.606	GBX 36,257	258.99
2025-09-25	BUY	110	328.710	332.737	332.334	GBX 36,557	258.60
2025-09-24	SELL	-5,597	329.840	331.150	331.019	GBX -1,852,713	258.20 Loss of -407,571 on sale
2025-09-18	BUY	71	342.890	343.280	343.241	GBX 24,370	257.72
2025-09-17	BUY	216	332.200	334.095	333.906	GBX 72,124	257.29
2025-09-11	SELL	-72	335.670	336.800	336.687	GBX -24,241	255.59 Loss of -5,839 on sale
2025-09-10	BUY	144	313.930	330.350	328.708	GBX 47,334	255.25
2025-09-05	SELL	-72	341.800	341.990	341.971	GBX -24,622	253.61 Loss of -6,362 on sale
2025-08-29	SELL	-216	306.050	314.900	314.015	GBX -67,827	252.09 Loss of -13,376 on sale
2025-08-27	BUY	144	300.140	301.290	301.175	GBX 43,369	251.51
2025-08-26	SELL	-72	308.910	309.680	309.603	GBX -22,291	251.15 Loss of -4,209 on sale
2025-08-25	BUY	72	308.630	320.000	318.863	GBX 22,958	250.79
2025-08-20	SELL	-288	309.330	310.610	310.482	GBX -89,419	250.01 Loss of -17,416 on sale
2025-08-18	BUY	144	319.320	330.630	329.499	GBX 47,448	249.16
2025-08-08	SELL	-144	288.180	290.675	290.425	GBX -41,821	247.58 Loss of -6,170 on sale
2025-08-05	BUY	72	307.230	310.490	310.164	GBX 22,332	246.48
2025-08-01	SELL	-215	299.010	299.290	299.262	GBX -64,341	245.72 Loss of -11,512 on sale
2025-07-30	BUY	288	299.940	306.580	305.916	GBX 88,104	244.95
2025-07-16	BUY	285	279.160	279.880	279.808	GBX 79,745	241.30
2025-07-11	SELL	-560	250.300	252.365	252.159	GBX -141,209	240.93 Loss of -6,286 on sale
2025-07-03	BUY	142	245.490	247.520	247.317	GBX 35,119	240.61
2025-07-02	BUY	3,905	244.320	244.650	244.617	GBX 955,229	240.58
2025-06-25	BUY	142	267.125	268.760	268.597	GBX 38,141	240.22
2025-06-20	BUY	332	247.080	248.300	248.178	GBX 82,395	239.79
2025-06-11	BUY	138	262.410	264.000	263.841	GBX 36,410	238.37
2025-06-10	BUY	138	263.420	264.850	264.707	GBX 36,530	238.14
2025-06-04	SELL	-69	258.270	261.930	261.564	GBX -18,048	237.35 Loss of -1,671 on sale
2025-04-23	BUY	69	249.130	255.055	254.462	GBX 17,558	235.66
2025-04-10	SELL	-552	208.310	222.170	220.784	GBX -121,873	236.10 Profit of 8,452 on sale
2025-04-08	SELL	-69	209.410	229.470	227.464	GBX -15,695	236.99 Profit of 657 on sale
2025-04-07	SELL	-69	220.540	235.030	233.581	GBX -16,117	237.26 Profit of 254 on sale
2025-04-04	SELL	-345	238.510	253.810	252.280	GBX -87,037	237.24 Loss of -5,190 on sale
2025-04-01	BUY	598	271.040	284.150	282.839	GBX 169,138	236.03
2025-03-31	SELL	-204	272.170	275.250	274.942	GBX -56,088	235.40 Loss of -8,066 on sale
2025-03-21	SELL	-279	251.980	256.490	256.039	GBX -71,435	233.02 Loss of -6,423 on sale
2025-03-14	SELL	-1,104	259.190	260.000	259.919	GBX -286,951	229.84 Loss of -33,210 on sale
2025-03-07	SELL	-138	247.070	256.525	255.579	GBX -35,270	227.68 Loss of -3,850 on sale
2025-03-04	SELL	-69	257.310	257.740	257.697	GBX -17,781	225.28 Loss of -2,237 on sale
2025-02-25	BUY	138	259.700	265.890	265.271	GBX 36,607	219.75
2025-02-19	SELL	-69	236.690	239.715	239.412	GBX -16,519	215.90 Loss of -1,623 on sale
2025-02-13	BUY	207	225.490	226.330	226.246	GBX 46,833	213.52
2025-02-12	BUY	69	223.310	226.675	226.339	GBX 15,617	213.13
2025-02-11	BUY	276	221.220	227.510	226.881	GBX 62,619	212.79
2025-01-17	BUY	276	210.080	211.960	211.772	GBX 58,449	189.30
2025-01-16	BUY	276	205.340	206.823	206.675	GBX 57,042	186.63
2025-01-10	SELL	-138	176.710	180.105	179.765	GBX -24,808	177.88 Loss of -260 on sale
2025-01-08	SELL	-276	177.880	177.990	177.979	GBX -49,122	0.00 Loss of -49,122 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ONC

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy